We are live on ! Find out more
BOCH

Blue Owl Capital Holdings Portfolio holdings

AUM $372M
1-Year Est. Return 78.25%
This Fund
S&P 500
This Quarter Est. Return
-13.36%
1 Year Est. Return
+78.25%
3 Year Est. Return
+112.77%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$360M
AUM Growth
-$141M
Cap. Flow
-$61.4M
Cap. Flow %
-17.07%
Top 10 Hldgs %
67.99%
Holding
55
New
10
Increased
7
Reduced
8
Closed
14

Top Buys

Rank Stock Value
1
CNTX icon
Context Therapeutics
CNTX
+$8.9M
2
VKTX icon
Viking Therapeutics
VKTX
+$6.23M
3
DM
Desktop Metal, Inc.
DM
+$4.62M
4
STWD icon
Starwood Property Trust
STWD
+$4.41M
5
PYXS icon
Pyxis Oncology
PYXS
+$4.4M

Top Sells

Rank Stock Value
1
HOOD icon
Robinhood
HOOD
+$54M
2
CGEM icon
Cullinan Oncology
CGEM
+$18.6M
3
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$5.02M
4
DELL icon
Dell
DELL
+$4.71M
5
LABD icon
Direxion Daily S&P Biotech Bear 3X ETF
LABD
+$3.57M

Sector Composition

Rank Sector Weight
1 Healthcare 71.57%
2 Technology 17.92%
3 Financials 8.96%
4 Real Estate 1.19%
5 Industrials 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CMPX icon
26
Compass Therapeutics
CMPX
$387M
$2.83M 0.79%
2,829,712
– –
ADCT icon
27
ADC Therapeutics
ADCT
$144M
$2.32M 0.64%
733,568
– –
OMGA
28
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$2.19M 0.61%
1,055,882
– –
GPCR icon
29
Structure Therapeutics
GPCR
$3.78B
$2.16M 0.6%
+55,000
New +$2.26M
IMVT icon
30
Immunovant
IMVT
$8.25B
$2.11M 0.59%
80,000
-20,000
-20% -$569K
SYRS
31
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$1.76M 0.49%
340,855
– –
JANX icon
32
Janux Therapeutics
JANX
$967M
$1.68M 0.47%
+40,000
New +$1.88M
CELC icon
33
Celcuity
CELC
$4.52B
$1.06M 0.3%
+65,000
New +$1.09M
BLND icon
34
Blend Labs
BLND
$386M
$853K 0.24%
361,587
– –
GOCO
35
DELISTED
GoHealth
GOCO
$815K 0.23%
83,264
– –
ENGNW icon
36
enGene Therapeutics Warrants
ENGNW
$608K 0.17%
51,177
-460,000
-90% -$1.47M
PLMJU
37
DELISTED
Plum Acquisition Corp. III Unit
PLMJU
$324K 0.09%
+70,000
New +$746K
DM
38
DELISTED
Desktop Metal, Inc.
DM
$310K 0.09%
750,000
+675,000
+900% +$4.62M
DTIL icon
39
Precision BioSciences
DTIL
$207M
$197K 0.05%
20,220
– –
GERN icon
40
Geron
GERN
$949M
$101K 0.03%
+23,918
New +$93.2K
PLMJW
41
DELISTED
Plum Acquisition Corp. III Warrant
PLMJW
$46.7K 0.01%
666,666
– –
BDTX icon
42
Black Diamond Therapeutics
BDTX
$112M
– –
-695,000
Closed -$3.52M
BRZE icon
43
Braze
BRZE
$2.99B
– –
-116,153
Closed -$2.36M
DELL icon
44
Dell
DELL
$293B
– –
-41,245
Closed -$4.71M
ELVN icon
45
Enliven Therapeutics
ELVN
$4.43B
– –
-25,000
Closed -$440K
GTLB icon
46
GitLab
GTLB
$6.58B
– –
-20,706
Closed -$1.21M
HOOD icon
47
Robinhood
HOOD
$83.9B
– –
-4,237,409
Closed -$54M
LABD icon
48
Direxion Daily S&P Biotech Bear 3X ETF
LABD
$57.2M
– –
-49,000
Closed -$3.57M
MDGL icon
49
Madrigal Pharmaceuticals
MDGL
$11.8B
– –
-13,319
Closed -$3.56M
MLTX icon
50
MoonLake Immunotherapeutics
MLTX
$1.55B
– –
-100,000
Closed -$5.02M
1
2
3

Similar funds

PC
Promethos Capital Boston, Massachusetts $372M AUM 23.19% 1-Year Est. Return
GIP
Gavilan Investment Partners Burlingame, California $372M AUM 6.04% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
KP
Kiltearn Partners Edinburgh, United Kingdom $372M AUM 18.16% 1-Year Est. Return
TCM
Thomist Capital Management Houston, Texas $371M AUM 77.62% 1-Year Est. Return
PAA
Peregrine Asset Advisers Portland, Oregon $371M AUM 41.36% 1-Year Est. Return
JC
Joho Capital New York $373M AUM 18.89% 1-Year Est. Return

Blue Owl Capital Holdings's Q2 2024 Portfolio in Review

As of Q2 2024, Blue Owl Capital Holdings held 55 positions worth $360M, down 28% from $501M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Blue Owl Capital Holdings withdrew a net $61.4M in Q2 2024, closing 14 positions and reducing 8 holdings. Its most notable exit was Robinhood, an estimated $54M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 67% a quarter earlier, followed by Technology and Financials.

Against the trend, Blue Owl Capital Holdings opened a new position in Context Therapeutics worth $10.3M.

  • Blue Owl Capital Holdings's largest Q2 2024 buy was Context Therapeutics: 5,161,290 shares worth $10.3M.
  • Blue Owl Capital Holdings added most to Desktop Metal, Inc. in Q2 2024, an estimated $4.62M increase.
  • Blue Owl Capital Holdings's biggest Q2 2024 reduction was Cullinan Oncology, cutting an estimated $18.6M.
  • Blue Owl Capital Holdings fully exited Robinhood in Q2 2024, selling an estimated $54M.
  • Blue Owl Capital Holdings's ten largest holdings make up 68% of its $360M portfolio in Q2 2024.
  • Blue Owl Capital Holdings opened 10 new positions and closed 14 in Q2 2024.
  • Blue Owl Capital Holdings's portfolio value fell 28% quarter-over-quarter to $360M.

Based on Blue Owl Capital Holdings's 13F filing for Q2 2024, filed 15 Aug 2024.